Export

EN
FR
Arsenic trioxide
Essential medicine status
Section:
8. Immunomodulators and antineoplastics 8.2. Antineoplastics and supportive medicines 8.2.1. Cytotoxic medicines
ATC codes: L01XX27
EMLc
Indication
Acute myeloid leukaemia with recurrent genetic abnormalities ICD11 code: 2B30.0
Medicine type
Chemical agent
List type
Complementary (EML)
(EMLc)
Formulations
Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion ; 2 mg per mL concentrate for solution for infusion
EML status history
First added in 2019 (TRS 1021)
Changed in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Wikipedia
Arsenic trioxide
DrugBank
Arsenic trioxide
Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of additional strength dosage form of aresnic trioxde (concentrate for solution for infusion 2 mg/mL) to the EML and EMLc.